On 17 June 2021, the US Food and Drug Administration (FDA) announced approval of a new nasal antihistamine (Astepro Allergy and Children’s Astepro Allergy) for nonprescription use. FDA described this as a “first-in-class switch” of a nasal antihistamine for seasonal and perennial allergies. It is a “partial switch” because the allergy indications for children under 6 years of age will remain prescription. PEGUS was privileged to support label development and comprehension testing, and warmly congratulates the sponsor on this new OTC product approval success.
Uncategorized
FDA Approves “First-in-Class” Nasal Antihistamine (Astepro Allergy) For OTC
Recent Posts
- Sterling IRB Features Pegus Research in Whitepaper Article Titled “PPC and Social Media Patient Recruitment: Strategies for Success”
- MHRA Approves Nuromol (Combined Paracetamol and Ibuprofen) for General Sale in UK
- FDA Approves “First-in-Class” Nasal Antihistamine (Astepro Allergy) For OTC
- Clark Richardson Participates in June 2021 FDA Public Workshop on the OTC Drug Facts Label
- PEGUS Announces Even More Enhancements to Its “Decentralized” Research Model
